PDA001 for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
Public ClinicalTrials.gov record NCT01155362. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Intravenous PDA001 for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This Phase 2a study evaluated the efficacy, safety, and tolerability of intravenous human placenta-derived cells (PDA001) compared with placebo in adults with moderate-to-severe Crohn's disease. Three PDA001 dose levels were evaluated.
Study identification
- NCT ID
- NCT01155362
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 50 participants
Conditions and interventions
Conditions
Interventions
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 2010 (Type not available)
- Primary completion
- Feb 2012 (Actual)
- Completion
- Apr 2014 (Actual)
- Last update posted
- Jul 7, 2026
2010 – 2014
United States locations
- U.S. sites
- 13
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Cedars Sinai Medical Center | Los Angeles | California | 90048 | — |
| University of California, Irvine | Orange | California | 92868 | — |
| Yale School of Medicine Digestive Diseases | New Haven | Connecticut | 06510 | — |
| University of Florida | Gainesville | Florida | 32610 | — |
| University of Chicago Medical Center | Chicago | Illinois | 60637 | — |
| Indiana University | Indianapolis | Indiana | 46202-5149 | — |
| Mt Sinai Hospital | New York | New York | 10029 | — |
| Rochester General Hospital | Rochester | New York | 14621 | — |
| Stony Brook University | Stony Brook | New York | 11794-8173 | — |
| Case Western Reserve University | Cleveland | Ohio | 44106-5066 | — |
| Vanderbilt University | Nashville | Tennessee | 37212 | — |
| Baylor College of Medicine | Houston | Texas | 77030 | — |
| McGuire VA Medical Center | Richmond | Virginia | 23249 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01155362, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 7, 2026 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01155362 live on ClinicalTrials.gov.